Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Identification of methylated genes associated with aggressive bladder cancer.

Marsit CJ, Houseman EA, Christensen BC, Gagne L, Wrensch MR, Nelson HH, Wiemels J, Zheng S, Wiencke JK, Andrew AS, Schned AR, Karagas MR, Kelsey KT.

PLoS One. 2010 Aug 23;5(8):e12334. doi: 10.1371/journal.pone.0012334.

2.

Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.

Kandimalla R, van Tilborg AA, Kompier LC, Stumpel DJ, Stam RW, Bangma CH, Zwarthoff EC.

Eur Urol. 2012 Jun;61(6):1245-56. doi: 10.1016/j.eururo.2012.01.011. Epub 2012 Jan 18.

PMID:
22284968
3.

DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer.

Marsit CJ, Koestler DC, Christensen BC, Karagas MR, Houseman EA, Kelsey KT.

J Clin Oncol. 2011 Mar 20;29(9):1133-9. doi: 10.1200/JCO.2010.31.3577. Epub 2011 Feb 22.

4.

Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers.

Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, Wiuf C, Borre M, Dyrskjøt L, Orntoft TF.

Clin Cancer Res. 2011 Sep 1;17(17):5582-92. doi: 10.1158/1078-0432.CCR-10-2659. Epub 2011 Jul 25.

5.

Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.

Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Miller K, Schrader M.

Int J Cancer. 2006 Sep 15;119(6):1396-402.

6.

Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.

Kitchen MO, Bryan RT, Haworth KE, Emes RD, Luscombe C, Gommersall L, Cheng KK, Zeegers MP, James ND, Devall AJ, Fryer AA, Farrell WE.

PLoS One. 2015 Sep 2;10(9):e0137003. doi: 10.1371/journal.pone.0137003. eCollection 2015.

7.

HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling.

Kim YJ, Yoon HY, Kim JS, Kang HW, Min BD, Kim SK, Ha YS, Kim IY, Ryu KH, Lee SC, Kim WJ.

Int J Cancer. 2013 Sep 1;133(5):1135-42. doi: 10.1002/ijc.28121. Epub 2013 Mar 16.

8.

Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer.

Shimizu T, Suzuki H, Nojima M, Kitamura H, Yamamoto E, Maruyama R, Ashida M, Hatahira T, Kai M, Masumori N, Tokino T, Imai K, Tsukamoto T, Toyota M.

Eur Urol. 2013 Jun;63(6):1091-100. doi: 10.1016/j.eururo.2012.11.030. Epub 2012 Nov 23.

PMID:
23200812
9.

RSPH9 methylation pattern as a prognostic indicator in patients with non-muscle invasive bladder cancer.

Yoon HY, Kim YJ, Kim JS, Kim YW, Kang HW, Kim WT, Yun SJ, Ryu KH, Lee SC, Kim WJ.

Oncol Rep. 2016 Feb;35(2):1195-203. doi: 10.3892/or.2015.4409. Epub 2015 Nov 11.

PMID:
26575865
10.

Diagnostic markers of urothelial cancer based on DNA methylation analysis.

Chihara Y, Kanai Y, Fujimoto H, Sugano K, Kawashima K, Liang G, Jones PA, Fujimoto K, Kuniyasu H, Hirao Y.

BMC Cancer. 2013 Jun 4;13:275. doi: 10.1186/1471-2407-13-275.

11.

Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles.

Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H, Vögeli TA, Grimm MO.

Clin Cancer Res. 2004 May 15;10(10):3410-21.

12.

Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays.

Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, Belbin TJ, Sanchez-Carbayo M.

Br J Cancer. 2008 Jan 29;98(2):466-73. Epub 2007 Dec 18.

13.

Identification of DNA methylation in 3' genomic regions that are associated with upregulation of gene expression in colorectal cancer.

Smith JF, Mahmood S, Song F, Morrow A, Smiraglia D, Zhang X, Rajput A, Higgins MJ, Krumm A, Petrelli NJ, Costello JF, Nagase H, Plass C, Held WA.

Epigenetics. 2007 Sep;2(3):161-72. Epub 2007 Jul 27.

PMID:
17965620
14.

Gene discovery in bladder cancer progression using cDNA microarrays.

Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ, Prystowsky MB, Ortiz AR, Childs G, Cordon-Cardo C.

Am J Pathol. 2003 Aug;163(2):505-16.

15.

DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection.

Negraes PD, Favaro FP, Camargo JL, Oliveira ML, Goldberg J, Rainho CA, Salvadori DM.

BMC Cancer. 2008 Aug 14;8:238. doi: 10.1186/1471-2407-8-238.

16.
17.

[Characterisation of DNA methylation biomarkers for bladder cancer].

Antony P, Rose M, Gaisa NT, Alkaya S, Heidenreich A, Knüchel R, Dahl E.

Pathologe. 2010 Oct;31 Suppl 2:244-50. doi: 10.1007/s00292-010-1367-1. German.

PMID:
20798943
18.

Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.

Yeh CM, Chen PC, Hsieh HY, Jou YC, Lin CT, Tsai MH, Huang WY, Wang YT, Lin RI, Chen SS, Tung CL, Wu SF, Chang DC, Shen CH, Hsu CD, Chan MW.

Oncotarget. 2015 Oct 6;6(30):29555-72. doi: 10.18632/oncotarget.4986.

19.

RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.

Yan C, Kim YW, Ha YS, Kim IY, Kim YJ, Yun SJ, Moon SK, Bae SC, Kim WJ.

J Surg Oncol. 2012 Mar 15;105(4):425-30. doi: 10.1002/jso.22087. Epub 2011 Aug 30.

PMID:
22311819
20.

A molecular signature in superficial bladder carcinoma predicts clinical outcome.

Dyrskjøt L, Zieger K, Kruhøffer M, Thykjaer T, Jensen JL, Primdahl H, Aziz N, Marcussen N, Møller K, Orntoft TF.

Clin Cancer Res. 2005 Jun 1;11(11):4029-36.

Supplemental Content

Support Center